Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Zofran Birth Defect Lawsuits Cleared to Proceed Toward Trial in MDL February 18, 2019 Irvin Jackson Add Your Comments The U.S. District Judge presiding over all federal Zofran lawsuits has rejected a request by the manufacturer to dismiss claims that allege the anti-nausea drug caused children to develop birth defects, clearing the way for a group of “bellwether” cases to continue preparations for early trial dates. GlaxoSmithKline currently faces more than 400 product liability lawsuits over Zofran, each raising similar allegations that the drug maker failed to adequately women and doctors about the potential side effects of Zofran during pregnancy, which may cause children to experience life-long health problems Zofran has been commonly prescribed “off-label” for symptoms of morning sickness, and complaints filed throughout the federal court system allege that exposure to the drug during pregnancy caused children to be born with cleft palates, cleft lips, atrial septal defects, ventricular septal defects and other congenital malformations. Learn More About Zofran Lawsuits Use of Zofran in Pregnancy May Increase the Risk that Children Suffer Cleft Palate, Cleft Lip, Heart Defects or Other Malformations. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Zofran Lawsuits Use of Zofran in Pregnancy May Increase the Risk that Children Suffer Cleft Palate, Cleft Lip, Heart Defects or Other Malformations. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Given the similar questions of fact and law presented in the litigation, cases filed in U.S. District Courts nationwide have been centralized for coordinated pretrial proceedings before U.S. District Judge Dennis Saylor in the District of Massachusetts, to reduce duplicative discovery, avoid conflicting pretrial rulings from different courts, and to serve the convenience of the parties, witnesses and the judicial system. On February 5, Judge Saylor issued a memorandum and order (PDF), denying a motion to for summary judgment filed by GlaxoSmithKline, which sought to dismiss all Zofran birth defects cases. The drug maker had argued that the plaintiffs’ failure to warn claims were preempted by federal law, but Saylor disagreed, indicating that there was no clear evidence that GlaxoSmithKline was prevented from strengthening Zofran label warnings. In addition, the Court found that there was not clear evidence that the FDA would have rejected such efforts; one of which would be necessary for the manufacturer to win the preemption argument. On the same day, Judge Saylor also issued an order scheduling the phases of case-specific discovery and Daubert and dispositive motions, indicating that the litigation is moving forward with preparations for a series of “bellwether” trials, which are designed to gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation. The pretrial schedule calls for depositions involving all case-specific experts to be concluded by May 24, 2019, and motions to exclude or limit case-specific expert testimony or opinions and case-specific dispositive motions to be filed by June 21. Families allege that GlaxoSmithKline knew or should have known about Zofran pregnancy risks for much longer than the last several years, yet withheld critical safety information, failed to warn doctors or consumers against use of the drug to treat morning sickness, and actively promoted the use during pregnancy, which was never approved by the FDA. As early as 2006, plaintiffs note studies have found Zofran crosses the placenta in significant amounts when taken by pregnant women, with Hong Kong researchers concluding that the “developmental significance of this drug exposure requires further investigation.” In November 2011, a study published in the medical journal Birth Defects Research Part A: Clinical and Molecular Teratology concluded that women may be 2.37 times more likely to give birth to a child with a cleft palate following Zofran use. This may leave children with a severe facial deformity, which can occur when development of the fetus is impacted during the first trimester. In August 2013, another study highlighted a potential risk of heart defects with Zofran, following a review of data involving more than 900,000 pregnancies in the Danish Medical Birth Registry. Researchers found that children may be two to four times more likely to suffer a septal defect, involving holes in the heart, following Zofran exposure. A study published by the medical journal Reproductive Toxicology in October 2014 found that there is a statistically significant increased risk for certain heart defects with Zofran use early in pregnancy. While the outcomes of any early “bellwether” trials will not be binding on other claims, they may greatly influence any Zofran settlement negotiations that would be necessary to avoid the need for hundreds of individual cases to go to trial in courts nationwide. Tags: Birth Defects, GlaxoSmithKline, Pregnancy, Zofran, Zofran Birth Defects Image Credit: | More Zofran Lawsuit Stories Trial Court Dismissal of Zofran Birth Defect Lawsuits Upheld on Appeal Before First Circuit January 10, 2023 Birth Defect Lawsuits Over Zofran Dismissed After Summary Judgment Granted on Federal Preemption June 7, 2021 First Bellwether Trial Over Zofran Birth Defects Set To Begin October 2021 March 5, 2021 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: today) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025) 12 Hair Dye Lawsuits Over Bladder Cancer Risks Assigned to One Judge in California State Court (Posted: yesterday) A dozen hair dye lawsuits over bladder cancer risks have been consolidated under one California state judge for coordinated pretrial proceedings. MORE ABOUT: HAIR DYE LAWSUITJudge To Meet With Hair Dye Lawyers in Bladder Cancer Lawsuit for Initial Status Conference (06/16/2025)Lawsuit Claims Paul Mitchell, Redken, Other Hair Dyes Led to Bladder Cancer Diagnosis for Hairdresser (05/09/2025)Salon Stylist Files Lawsuit Over Bladder Cancer From Hair Dye Products (05/02/2025) BioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (Posted: 2 days ago) Following a Class I recall, more than 100 BioZorb lawsuits have been filed by breast cancer survivors who suffered painful complications after the surgical tissue marker failed to dissolve as intended. MORE ABOUT: BIOZORB LAWSUITLawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)
Trial Court Dismissal of Zofran Birth Defect Lawsuits Upheld on Appeal Before First Circuit January 10, 2023
Birth Defect Lawsuits Over Zofran Dismissed After Summary Judgment Granted on Federal Preemption June 7, 2021
Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: today) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)
12 Hair Dye Lawsuits Over Bladder Cancer Risks Assigned to One Judge in California State Court (Posted: yesterday) A dozen hair dye lawsuits over bladder cancer risks have been consolidated under one California state judge for coordinated pretrial proceedings. MORE ABOUT: HAIR DYE LAWSUITJudge To Meet With Hair Dye Lawyers in Bladder Cancer Lawsuit for Initial Status Conference (06/16/2025)Lawsuit Claims Paul Mitchell, Redken, Other Hair Dyes Led to Bladder Cancer Diagnosis for Hairdresser (05/09/2025)Salon Stylist Files Lawsuit Over Bladder Cancer From Hair Dye Products (05/02/2025)
BioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (Posted: 2 days ago) Following a Class I recall, more than 100 BioZorb lawsuits have been filed by breast cancer survivors who suffered painful complications after the surgical tissue marker failed to dissolve as intended. MORE ABOUT: BIOZORB LAWSUITLawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)